Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment

Journal of Immunology

Volumn 163, Issue 4, 1999, Pages 2330-2338

  Calarota, Sandra A ^a   Leandersson, Ann Charlotte ^a   Bratt, Göran ^b   Hinkula, Jorma ^a   Klinman, Dennis M ^c   Weinhold, Kent J ^d   Sandström, Eric ^b   Wahren, Britta ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM SÖDER HOSPITAL   (Sweden)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; DNA VACCINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; INDINAVIR; INTERLEUKIN 6; LAMIVUDINE; NEF PROTEIN; REV PROTEIN; TRANSACTIVATOR PROTEIN; ZIDOVUDINE;

ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS LOAD;

AIDS VACCINES; ANTI-HIV AGENTS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CD4 LYMPHOCYTE COUNT; COMBINED MODALITY THERAPY; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; DRUG THERAPY, COMBINATION; EPITOPES, T-LYMPHOCYTE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; STEM CELLS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VIRAL LOAD;

EID: 0033566813     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune response with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650.
2. + cytotoxic T lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103.
3. + T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc. Natl. Acad. Sci. USA 92:2308.
4. Toso, J. F., C.-H. Chen, J. R. Mohr, L. Piglia, C. Oei, G. Ferrari, M. L. Greenberg, and K. J. Weinhold. 1995. Oligoclonal CD8 lymphocytes from persons with asymptomatic human immunodeficiency virus (HIV) type 1 infection inhibit HIV-1 replication. J. Infect. Dis. 172:964.
5. Klein, M. R., C. A. van Baalen, A. M. Holwerda, S. R. Kerkhof Garde, R. J. Bende, I. P. M. Keet, J. M. Eeftinck-Schattenker, A. D. M. E. Osterhaus, and F. Miedema. 1995. Kinetics of Gag-specific CTL responses during the clinical course of HIV-1 infection: different for rapid progressors and long-term asymptomatics. J. Exp. Med. 181:1365.
6. Rinaldo, C., X.-L. Huang, Z. Fan, M. Ding, L. Beltz, A. Logar, D. Panicali, G. Mazzara, J. Liebmann, M. Cottrill, and P. Gupta. 1995. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69:5838.
7. van Baalen, C. A., O. Pontesilli, R. C. Huisman, A. M. Geretti, M. R. Klein, F. de Wolf, F. Miedema, R. A. Gruters, and A. D. M. E. Osterhaus. 1997. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J. Gen. Virol. 78:1913.
8. Shearer, G. M., and M. Clerici. 1991. Early T-helper cell defects in HIV infection. AIDS 5:245.
9. Wahren, B., L. Morfeldt-Månsson, G. Biberfeld, L. Moberg, P. Ljungman, S. Nordlund, U. Bredberg-Rådén, A. Werner, J. Löwer, and R. Kurth. 1986. Impaired specific cellular response to HTLV-III before other immune defects in patients with HTLV-III infection. N. Engl. J. Med. 315:393.
10. + T cell responses associated with control of viremia. Science 278:1447.
11. Wahren, B., G. Bratt, C. Persson, B. Levén, J. Hinkula, G. Gilljam, S. Nordlund, L. Eriksson, F. Volvovitz, P. A. Broliden, and E. Sandström. 1994. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp106. J. Acquir. Immune Defic. Syndr. 7:220.
12. Redfield, R. R., D. L. Birx, N. Ketter, E. Tramont, V. Polonis, C. Davis, J. F. Brundage, G. Smith, S. Johnson, A. Fowler, T. Wierzba, A. Shafferman, F. Volvovitz, C. Oster, D. Burke, and the Military Medical Consortium for Applied Retroviral Research. 1991. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N. Engl. J. Med. 324:1677.
13. Levine, A. M., S. Groshen, J. Allen, K. M. Munson, D. J. Carlo, A. E. Daigle, F. Ferre, F. C. Jensen, S. P. Richieri, R. J. Trauger, et al. 1996. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 immunogen: long-term follow-up. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 11:351.
14. Leandersson, A.-C., G. Bratt, J. Hinkula, G. Gilljam, P. Cochaux, M. Samson, E. Sandström, and B. Wahren. 1998. Induction of specific T-cell responses in HIV infection. AIDS 12:157.
15. Ulmer, J. B., J. J. Donnelly, S. E. Parker, G. H. Rhodes, P. L. Felgner, V. J. Dwerki, S. H. Gromkowski, R. R. Deck, C. M. DeWitt, A. Friedman, et al. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745.
16. Tighe, H., M. Corr, M. Roman, and E. Raz. 1998. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol. Today 19:89.
17. Wang, B., J. Boyer, V. Srikantan, L. Coney, R. Carrano, C. Phan, M. Merva, K. Dang, M. Agadjanyan, L. Gilbert, et al. 1993. DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates. DNA Cell. Biol. 12:799.
18. Heydenburg-Fuller, D., and J. R. Haynes. 1994. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. AIDS Res. Hum. Retroviruses 10:1433.
19. Yasutomi, Y., H. L. Robinson, S. Lu, F. Mustafa, C. Lekutis, J. Arthos, J. I. Mullins, G. Voss, K. Manson, M. Wyand, and N. L. Letvin. 1996. Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. J. Virol. 70:678.
20. Boyer, J. D., K. E. Ugen, B. Wang, M. Agadanyan, L. Gilbert, M. L. Bagarazzi, M. Chattergoon, P. Frost, A. Javadian, W. V. Williams, et al. 1997. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat. Med. 3:525.
21. MacGregor, R. R., J. D. Boyer, K. E. Ugen, K. E. Lacy, S. J. Gluckman, M. L. Bagarazzi, M. A. Chattergoon, Y. Baine, T. J. Higgins, R. B. Ciccarelli, et al. 1998. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J. Infect. Dis. 178:92.
22. Wang, R., D. L. Doolan, T. P. Le, R. C. Hedstrom, K. M. Coonan, Y. Charoenvit, T. R. Jones, P. Hobart. M. Margalith, J. Ng, et al. 1998. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282:476.
23. Calarota, S., G. Bratt, S. Nordlund, J. Hinkula, A.-C. Leandersson, E. Sandström, and B. Wahren. 1998. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351:1320.
24. Mermer, B., B. K. Felber, M. Campbell, and G. N. Pavlakis. 1990. Identification of trans-dominant HIV-1 rev protein mutants by direct transfer of bacterially produced proteins into human cells. Nucleic Acids Res. 18:2037.
25. Hinkula, J., C. Svanholm, S. Schwartz, P. Lundholm, M. Brytting, G. Engström, R. Benthin, H. Glaser, G. Sutter, B. Kohleisen, et al. 1997. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J. Virol. 71:5528.
26. Hinkula, J., P. Lundholm, and B. Wahren. 1997. Nucleic acid vaccination with HIV regulatory genes: a combination of HIV-1 genes in separate plasmids induces strong immune responses. Vaccine 15:874.
27. Kjerrström, A., and B. Wahren. 1999. Expression of HIV regulatory DNA vaccine constructs. Biogenic Amines 15:93.
28. Sabatier, J. M., B. Clerget-Raslain, G. Fontan, E. Fenouillet, H. Rochat, C. Granier, J. C. Gluckman, J. van Rietschoten, L. Montagnier, and E. Bahraoui. 1989. Use of synthetic peptides for the detection of antibodies against the nef regulating protein in sera of HIV-infected patients. AIDS 3:215.
29. Ranki, A., A. Lagerstedt, V. Ovod, E. Aavik, and K. J. E. Krohn. 1994. Expression kinetics and subcellular localization of HIV-1 regulatory proteins nef, tat, and rev and chronically infected lymphoid cell lines. Arch. Virol. 139:365.
30. Myers, G., B. H. Hahn, J. W. Mellors, L. E. Henderson, B. Korber, K.-T. Jeang, F. E. McCurchan, and G. N. Pavlakis, eds. 1995. Human Retroviruses and AIDS: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Los Alamos National Laboratory, Los Alamos, NM.
31. Spector, D. H., E. Wade, D. A. Wright, V. Koval, C. Clark, D. Jaquish, and S. A. Spector. 1990. Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J. Virol. 64:2298.
32. Ferrari, G., C. Berend, J. Ottinger, R. Dodge, J. Bartlett, J. Toso, D. Moody, J. Tartaglia, W. I. Cox, E. Paoletti, and K. J. Weinhold. 1997. Replication-defective Canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy. Blood 90:2406.
33. Hinkula, J., J. Rosen, V.-A. Sundqvist, T. Stigbrand, and B. Wahren. 1990. Epitope mapping of the HIV-1 gag region with monoclonal antibodies. Mol. Immunol. 5:395.
34. Geretti, A. M., M. E. M. Dings, C. A. C. M. van Els, C. A. van Baalen, F. J. Wijnholds, J. C. C. Borleffs, and A. D. M. E. Osterhaus. 1996. Human immunodeficiency virus type 1 (HIV-1)- and Epstein-Barr virus-specific cytotoxic T lymphocyte precursors exhibit different kinetics in HIV-1-infected persons. J. Infect. Dis. 174:34.
35. Klinman, D. M., and T. B. Nutman. 1994. ELIspot assay to detect cytokine-secreting murine and human cells. In Current Protocols in Immunology. J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober. eds. Greene Publishing Associates, Brooklyn, NY, pp. 6.19.1-6.19.8.
36. Hagiwara, E., F. Abbasi, G. Mor, Y. Ishigatsubo, and D. M. Klinman. 1995. Phenotype and frequency of cells secreting IL-2, IL-4, IL-6, IL-10, IFN-γ and TNF-α in human peripheral blood. Cytokine 7:815.
37. Carpenter, C. C. J., M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. G. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, et al. 1997. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. J. Am. Med. Assoc. 277: 1962.
38. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm. et al. 1997. Treatment with Indinavir, Zidovudine, and Lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734.
39. Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, J. E. Feinberg, H. H. Balfour, L. R. Deyton, J. A. Chodakewitz, and M. A. Fischl, for the AIDS Clinical Trials Group 320 Study Team. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337:725.
40. Klinman, D. M., G. Yamshchikov, and Y. Ishigatsubo. 1997. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J. Immunol. 158:3635.
41. Roman, M., E. Martin-Orozco, J. S. Goodman, M.-D. Nguyen, Y. Sato, A. Ronaghy, R. S. Kornbluth, D. D. Richman, D. A. Carson, and E. Raz. 1997. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3:849.
42. Krieg, A. M., A. K. Yi, J. Schorr, and H. L. Davis. 1998. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol. 6:23.
43. Davis, H. L., R. Weeranta, T. J. Waldschmidt, L. Tygrett, J. Schorr, and A. M. Krieg. 1998. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160:870.
44. Ogg, G. S., X. Jin, S. Bonhoeffer, P. Rod Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, et al. 1998. Quantification of HIV-1-specific cytotoxic T lymphocytes and plasma viral load of viral RNA. Science 279:2103.
45. Dadold, M., M. Harzic, I. Pellegrin, B. Dumon, B. Hoen, D. Sereni, J.-C. Deschemin, J.-P. Levy, A. Venet, and E. Gomard. 1998. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. J. Infect. Dis. 178:61.
46. Reiss, P., A. de Ronde, J. M. A. Lange, F. de Wolf, J. Dekker, S. A. Danner, C. Debouck, and J. Goudsmit. 1989. Low antigenicity of HIV-1 rev: rev-specific antibody response of limited value as correlate of rev gene expression and disease progression. AIDS. Res. Hum. Retroviruses 5:621.
47. Wahren, B., J. Hinkula, E. Ljungdahl Ståhle, C. A. K. Borrebaeck, S. Schwartz, and H. Wigzell. 1995. Nucleic acid vaccination with HIV regulatory genes. Ann. NY Acad. Sci. 772:278.
48. Robert-Guroff, M., M. Popovic, S. Gartner, P. Markham, R. C. Gallo, and M. S. Reitz. 1990. Structure and expression of tat-, rev-, and nef-specific transcripts of human immunodeficiency virus type 1 in infected lymphocytes and macrophages. J. Virol. 64:3391.
49. Harris, M. 1996. From negative factor to a critical role in virus pathogenesis: the changing fortunes of Nef. J. Gen. Virol. 77:2379.
50. Cullen, B. R. 1998. HIV-1 auxiliary proteins: making connections in a dying cell. Cell 93:685.
51. Rosenberg, E. S., and B. D. Walker. 1998. HIV type 1-specific helper T cells: a critical host defense. AIDS Res. Hum. Retroviruses 14:S143.